Major Depressive Symptoms Increase 3-Year Mortality Rate in Patients with Mild Dementia

Depression and dementia are commonly concurrent and are both associated with increased mortality among older people. However, little is known about whether home-dwelling patients newly diagnosed with mild dementia coexisting with depressive symptoms have excess mortality. We conducted a post hoc analysis based on data from the Danish Alzheimer’s Intervention Study of 330 individuals who were diagnosed with mild dementia within the past 12 months. Thirty-four patients were identified with major depressive symptoms (MD-S) at baseline. During the 3-year follow-up period, 56 patients died, and, among them, 12 were with MD-S at baseline. Multivariable analysis adjusting for the potential confounders (age, sex, smoking status, alcohol consumption, education, BMI, household status, MMSE, CCI, QoL-AD, NPIQ, ADSC-ADL, medication, and RCT allocation) showed that patients with MD-S had a 2.5-fold higher mortality as compared to the patients without or with only few depressive symptoms. Our result revealed that depression is possibly associated with increased mortality in patients with mild dementia. Given that depression is treatable, screening for depression and treatment of depression can be important already in the earliest stage of dementia to reduce mortality.

Download Full-text

ASSESSMENT OF PREVALENCE OF DEPRESSION IN CARDIAC PATIENTS AND ITS ASSOCIATION WITH THE USE OF BETA-BLOCKERS AND STATINS

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i12.28444 ◽

2018 ◽

Vol 11 (12) ◽

pp. 416

Author(s):

Krutika Desai ◽

Neha Diwan ◽

Perin Devi Mudhiganti ◽

Anand V Joshi ◽

Narender Boggula ◽

...

Keyword(s):

Cardiovascular Disease ◽

Depressive Symptoms ◽

Major Depression ◽

Beta Blockers ◽

Cardiac Patients ◽

Major Depressive ◽

Prevalence Of Depression ◽

Β Blockers ◽

Major Depressive Symptoms

Objective: The objective of the study is to assess the prevalence of depression among patients with cardiovascular disease and its association with the use of β-blockers and statins.Methods: This is a prospective observational study conducted at a corporate hospital, Hyderabad, Telangana, India, for a period of 6 months. 250 cardiac patients above 16 years are included in the study. The required data are collected from the patients through direct interview using standard questionnaires and also from patients’ respective case sheets. The acquired data are evaluated based on the standard questionnaires Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory-II (BDI-II) scales; used to diagnose the severity of depression in cardiac patients.Results: Prevalence of minor to major depressive symptoms according to BDI-II was found to be 17.2%. Prevalence of minor to major depressive symptoms according to PHQ-9 was found to be 19.2%. Among male patients, 13% showed depressive symptoms, whereas among female patients 25% showed depressive symptoms. Among the patients coadministering beta-blockers and statins, 15% were depressed according to BDI-II, and 16% were depressed according to PHQ-9 at visit. After 1 month (first follow-up), the percentage increased by 8% (for BDI-II)-12% (for PHQ-9) and remains almost the same at the second follow-up. As per BDI-II and PHQ-9 scores, the percentage of patients with minor to major depression among the patients using only beta-blockers decreased significantly from the time of visit to the second follow-up. The percentage of patients with minor to major depression among the patients using only statins increased significantly from the time of visit to second follow-up.Conclusion: Prevalence of minor to major depression according to BDI-II was found to be 17%, whereas according to PHQ-9, it was found to be 20% in patients with cardiovascular disease. Cardiovascular diseases have been more prevalent in men than in women, whereas depressive symptoms have been more prevalent in women than in men. Patients using only β-blockers showed a decrease in symptoms of depression. Whereas statins have shown to increase the chances of depression slightly which is often negligible, atorvastatin was associated with a higher level of depression when compared to rosuvastatin. Controversies still exist that statins decrease risk of depression.

Download Full-text

Major depressive symptoms and escalation of drinking among new drinkers in the United States: Variations across sex and age groups

Addictive Behaviors ◽

10.1016/j.addbeh.2021.107017 ◽

2021 ◽

pp. 107017

Author(s):

Hui G. Cheng ◽

Alexis C. Edwards

Keyword(s):

United States ◽

Depressive Symptoms ◽

Age Groups ◽

The United States ◽

Major Depressive ◽

Major Depressive Symptoms

Download Full-text

Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study

Epidemiology and Psychiatric Sciences ◽

10.1017/s2045796020000438 ◽

2020 ◽

Vol 29 ◽

Author(s):

C. E. Lloyd ◽

N. Sartorius ◽

H. U. Ahmed ◽

A. Alvarez ◽

S. Bahendeka ◽

...

Keyword(s):

Type 2 Diabetes ◽

Major Depressive Disorder ◽

Depressive Symptoms ◽

Depressive Disorder ◽

Life Events ◽

Stressful Life Events ◽

Regression Analyses ◽

Major Depressive

Abstract Aims To examine the factors that are associated with changes in depression in people with type 2 diabetes living in 12 different countries. Methods People with type 2 diabetes treated in out-patient settings aged 18–65 years underwent a psychiatric assessment to diagnose major depressive disorder (MDD) at baseline and follow-up. At both time points, participants completed the Patient Health Questionnaire (PHQ-9), the WHO five-item Well-being scale (WHO-5) and the Problem Areas in Diabetes (PAID) scale which measures diabetes-related distress. A composite stress score (CSS) (the occurrence of stressful life events and their reported degree of ‘upset’) between baseline and follow-up was calculated. Demographic data and medical record information were collected. Separate regression analyses were conducted with MDD and PHQ-9 scores as the dependent variables. Results In total, there were 7.4% (120) incident cases of MDD with 81.5% (1317) continuing to remain free of a diagnosis of MDD. Univariate analyses demonstrated that those with MDD were more likely to be female, less likely to be physically active, more likely to have diabetes complications at baseline and have higher CSS. Mean scores for the WHO-5, PAID and PHQ-9 were poorer in those with incident MDD compared with those who had never had a diagnosis of MDD. Regression analyses demonstrated that higher PHQ-9, lower WHO-5 scores and greater CSS were significant predictors of incident MDD. Significant predictors of PHQ-9 were baseline PHQ-9 score, WHO-5, PAID and CSS. Conclusion This study demonstrates the importance of psychosocial factors in addition to physiological variables in the development of depressive symptoms and incident MDD in people with type 2 diabetes. Stressful life events, depressive symptoms and diabetes-related distress all play a significant role which has implications for practice. A more holistic approach to care, which recognises the interplay of these psychosocial factors, may help to mitigate their impact on diabetes self-management as well as MDD, thus early screening and treatment for symptoms is recommended.

Download Full-text

Cigarette dependence and depressive symptoms as predictors of smoking status at five-year follow-up after a workplace smoking cessation program

Addictive Behaviors ◽

10.1016/j.addbeh.2017.04.003 ◽

2017 ◽

Vol 73 ◽

pp. 9-15 ◽

Cited By ~ 2

Author(s):

Gemma Nieva ◽

Marina Comín ◽

Sergi Valero ◽

Eugeni Bruguera

Keyword(s):

Smoking Cessation ◽

Depressive Symptoms ◽

Smoking Status ◽

Smoking Cessation Program ◽

Workplace Smoking ◽

Cigarette Dependence

Download Full-text

Abstract P485: Predictors and Clinical Impact of Deep Grey Matter Infarction After Endovascular Treatment for Large Vessel Occlusion Stroke: Results From the Escape-NA1 Trial

Stroke ◽

10.1161/str.52.suppl_1.p485 ◽

2021 ◽

Vol 52 (Suppl_1) ◽

Author(s):

Johanna Ospel ◽

Michael D Hill ◽

Nima Kashani ◽

Arnuv Mayank ◽

Nishita Singh ◽

...

Keyword(s):

Grey Matter ◽

Infarct Volume ◽

Multivariable Analysis ◽

Diffusion Weighted Mri ◽

Vessel Occlusion ◽

Lentiform Nucleus ◽

Good Outcome ◽

Deep Grey Matter ◽

Post Hoc

Purpose: In this post-hoc analysis of the ESCAPE-NA1 trial, we investigated the prevalence of deep grey matter infarcts and their influence on clinical outcome. Methods: Infarcts on 24 hour follow up imaging (non contrast head CT or diffusion-weighted MRI) were categorized as predominantly deep grey matter infarcts (caudate and/or lentiform nucleus infarcts with sparing of the superficial grey matter and white matter) vs. other infarcts. Total infarct volume was manually segmented in all patients. When MRI follow-up was available, deep grey matter and grey matter infarct volumes were segmented separately. Multivariable logistic regression with adjustment for key minimization variables and by infarct volume was used to assess the association of predominantly deep grey matter infarcts and good outcome. Results: Of the 1026 included patients, 316 (30.8%) had predominantly deep grey matter infarcts. Cumulative proportions of good outcome for overall, grey matter, deep grey matter, and superficial grey matter infarct volumes are shown in the figure. Good outcomes were more frequently achieved in patients with predominantly deep grey matter infarcts (239/316 [75.6%] vs. 374/704 [53.1%]). Deep infarcts were tightly correlated with infarct volume (Pearson rho -0.35) and in multivariable analysis deep grey matter infarcts were predictive of outcome overall; when examined in volume percentiles, there was no effect of deep infarct location. Conclusion: Predominantly deep grey matter infarcts are associated with good outcomes. Deep grey matter infarct location favorable prognosis is associated with small overall infarct size.

Download Full-text

Associations between major depressive symptoms and drinking onset: Do sex and age matter?

Journal of Affective Disorders ◽

10.1016/j.jad.2020.01.176 ◽

2020 ◽

Vol 266 ◽

pp. 549-555 ◽

Cited By ~ 1

Author(s):

Hui G. Cheng ◽

Kenneth S. Kendler ◽

Alexis C. Edwards

Keyword(s):

Depressive Symptoms ◽

Major Depressive ◽

Major Depressive Symptoms

Download Full-text

Improvement in social-interpersonal functioning after cognitive therapy for recurrent depression

Psychological Medicine ◽

10.1017/s0033291703001478 ◽

2004 ◽

Vol 34 (4) ◽

pp. 643-658 ◽

Cited By ~ 43

Author(s):

J. R. VITTENGL ◽

L. A. CLARK ◽

R. B. JARRETT

Keyword(s):

Depressive Symptoms ◽

Cognitive Therapy ◽

Acute Phase ◽

Social Adjustment ◽

Interpersonal Problems ◽

Dyadic Adjustment ◽

Interpersonal Functioning ◽

Major Depressive ◽

Continuation Phase

Background. Cognitive therapy reduces depressive symptoms of major depressive disorder, but little is known about concomitant reduction in social-interpersonal dysfunction.Method. We evaluated social-interpersonal functioning (self-reported social adjustment, interpersonal problems and dyadic adjustment) and depressive symptoms (two self-report and two clinician scales) in adult outpatients (n=156) with recurrent major depressive disorder at several points during a 20-session course of acute phase cognitive therapy. Consenting acute phase responders (n=84) entered a 2-year follow-up phase, which included an 8-month experimental trial comparing continuation phase cognitive therapy to assessment-only control.Results. Social-interpersonal functioning improved after acute phase cognitive therapy (dyadic adjustment d=0·47; interpersonal problems d=0·91; social adjustment d=1·19), but less so than depressive symptoms (d=1·55). Improvement in depressive symptoms and social-interpersonal functioning were moderately to highly correlated (r=0·39–0·72). Improvement in depressive symptoms was partly independent of social-interpersonal functioning (r=0·55–0·81), but improvement in social-interpersonal functioning independent of change in depressive symptoms was not significant (r=0·01–0·06). In acute phase responders, continuation phase therapy did not further enhance social-interpersonal functioning, but improvements in social-interpersonal functioning were maintained through the follow-up.Conclusions. Social-interpersonal functioning is improved after acute phase cognitive therapy and maintained in responders over 2 years. Improvement in social-interpersonal functioning is largely accounted for by decreases in depressive symptoms.

Download Full-text

Change in Pain Severity With Open Label Venlafaxine Use in Patients With a Depressive Symptomatology: An Observational Study in Primary Care

European Psychiatry ◽

10.1016/j.eurpsy.2008.01.001 ◽

2008 ◽

Vol 23 (3) ◽

pp. 178-186 ◽

Cited By ~ 8

Author(s):

Stefan Begré ◽

Martin Traber ◽

Martin Gerber ◽

Roland von Känel

Keyword(s):

Primary Care ◽

Chronic Pain ◽

Depressive Symptoms ◽

Observational Study ◽

Primary Care Physicians ◽

Depressive Symptomatology ◽

Dose Finding ◽

Open Label ◽

Treatment Of Depression

AbstractPurpose.Venlafaxine has shown benefit in the treatment of depression and pain. Worldwide data are extensively lacking investigating the outcome of chronic pain patients with depressive symptoms treated by venlafaxine in the primary care setting. This observational study aimed to elucidate the efficacy of venlafaxine and its prescription by Swiss primary care physicians and psychiatrists in patients with chronic pain and depressive symptomatology.Subjects and methods.We studied 505 patients with depressive symptoms suffering from chronic pain in a prospective naturalistic Swiss community based observational trial with venlafaxine in primary care. These patients have been treated with venlafaxine by 122 physicians, namely psychiatrists, general practitioners, and internists.Results.On average, patients were treated with 143 ± 75 mg (0–450 mg) venlafaxine daily for a follow-up of three months. Venlafaxine proved to be beneficial in the treatment of both depressive symptoms and chronic pain.Discussion.Although side effects were absent in most patients, physicians might have frequently omitted satisfactory response rate of depression by underdosing venlafaxine. Our results reflect the complexity in the treatment of chronic pain in patients with depressive symptoms in primary care.Conclusion.Further randomized dose-finding studies are needed to learn more about the appropriate dosage in treating depression and comorbid pain with venlafaxine.

Download Full-text